dc.contributor.author | İçli, Abdullah | |
dc.contributor.author | Cüre, Erkan | |
dc.contributor.author | Cüre, Medine Cumhur | |
dc.contributor.author | Uslu, Ali Uğur | |
dc.contributor.author | Balta, Şevket | |
dc.contributor.author | Mikhailidis, Dimitri P. | |
dc.contributor.author | Öztürk, Cengiz | |
dc.contributor.author | Arslan, Şevket | |
dc.contributor.author | Sakız, Davut | |
dc.contributor.author | Şahin, Muhammed | |
dc.contributor.author | Küçük, Adem | |
dc.date.accessioned | 2020-12-19T19:50:22Z | |
dc.date.available | 2020-12-19T19:50:22Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Icli, A., Cure, E., Cure, M. C., Uslu, A. U., Balta, S., Mikhailidis, D. P., Ozturk, C., Arslan, S., Sakız, D., Sahin, M., & Kucuk, A. (2016). Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology, 67(8), 749–755. https://doi.org/10.1177/0003319715616240 | en_US |
dc.identifier.issn | 0003-3197 | |
dc.identifier.issn | 1940-1574 | |
dc.identifier.uri | https://doi.org/10.1177/0003319715616240 | |
dc.identifier.uri | https://hdl.handle.net/11436/2421 | |
dc.description | Cure, Medine Cumhur/0000-0001-9253-6459; Mikhailidis, Dimitri/0000-0002-9566-2263; cure, erkan/0000-0001-7807-135X; Balta, Sevket/0000-0002-6657-7334 | en_US |
dc.description | WOS: 000382857900007 | en_US |
dc.description | PubMed: 26614790 | en_US |
dc.description.abstract | Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. A major cause of morbidity and mortality in SLE is accelerated atherosclerosis. Endothelial-specific molecule 1 (endocan) is a potential predictor of vascular events and is expressed in response to inflammatory cytokines in endothelial cells. We investigated the relationship between endocan and carotid intima-media thickness (cIMT) as a marker of early atherosclerosis. We included 44 women with SLE and 44 healthy women as controls. Disease severity of SLE was evaluated using the SLE Disease Activity Index. Endocan, C-reactive protein, erythrocyte sedimentation rate (ESR), and lipid panel were measured. the cIMT was 0.70 (range: 0.45-1.20) mm in patients with SLE and 0.40 (0.25-0.60) mm in controls (P < .001). Endocan value was 1.6 +/- 0.9 ng/mL in controls and 2.2 +/- 1.0 ng/mL in patients with SLE (P = .014). Endocan levels were positively correlated with cIMT (r = .469, P < .001), body mass index (r = .373, P = .013), and ESR (r = .393, P = .008). Endocan level may be associated with subclinical atherosclerosis in SLE. Consequently, endocan levels may be a promising clinical tool for patients with SLE as a guide for preventive strategy. | en_US |
dc.description.sponsorship | MSD; AstraZenecaAstraZeneca; Libytec | en_US |
dc.description.sponsorship | The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DPM has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Sage Publications Inc | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Endocan | en_US |
dc.subject | Systemic lupus erythematosus | en_US |
dc.subject | Atherosclerosis | en_US |
dc.subject | Inflammation | en_US |
dc.title | Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Cüre, Erkan | |
dc.contributor.institutionauthor | Cüre, Medine Cumhur | |
dc.identifier.doi | 10.1177/0003319715616240 | |
dc.identifier.volume | 67 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 749 | en_US |
dc.identifier.endpage | 755 | en_US |
dc.relation.journal | Angiology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |